psychedelics-investing Emyria and UWA in Partnership to Commercialise Novel Serotonin-Releasing Agents for Mental Health and Neurology
psychedelics-investing Quarterly Activities Report: Melodiol Delivers $9.3m in Revenue During H1 FY24 – a 33% Increase the PCP
psychedelics-investing $12M Proposed Cash Asset Sale to Strengthen Balance Sheet, with $2.2M of Earn Outs
psychedelics-investing Emyria Selected by Reach Wellness to Lead MDMA -Assisted Therapy Research for First Responders
